Loading...
01/11 03:38
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects mixed signals: While there are positive developments like new product launches and restructuring efforts, there are concerns over conversion rates, economic challenges, and unmet expectations in key markets. The guidance suggests modest growth, but economic uncertainties and patient reluctance pose risks. The sentiment from the Q&A indicates cautious optimism but lacks strong catalysts for a significant positive shift. Overall, the stock is likely to remain stable, with a neutral impact expected over the next two weeks.
Total Q2 Revenues $1.012 billion, down 1.6% year-over-year. The decline was attributed to lower-than-expected sales of full iTero Lumina Systems and a slight year-over-year decrease in clear aligners revenues, driven primarily by lower-than-expected volumes in Europe and North America.
Systems and Services Revenues $207.8 million, up 5.6% year-over-year. Growth was driven by solid revenue from iTero Lumina wand upgrades and increased services as more doctors transitioned to iTero Element 5D Plus and advanced iTero Lumina.
Clear Aligner Revenues $804.6 million, down 3.3% year-over-year. The decline was due to lower ASPs from discounts and product mix shift to lower-priced products, partially offset by a price increase and favorable foreign exchange.
Clear Aligner Volume Slight year-over-year increase. Growth was observed in APAC and EMEA regions, offset by a decline in the Americas. The growth was driven by products like Invisalign First, DSP touch-up cases, and Invisalign palate expander.
Gross Margin 69.9%, down 0.3 points year-over-year. The decline was primarily due to lower ASPs, partially offset by freight savings and favorable foreign exchange.
Operating Expenses $545.1 million, down 5.3% year-over-year. The decrease was primarily due to lower legal settlements not recurring in Q2 2025.
Operating Margin 16.1%, up 1.7 points year-over-year. The improvement was driven by cost management and favorable foreign exchange.
Net Income Per Diluted Share (GAAP) $1.72, up $0.43 year-over-year. The increase was favorably impacted by foreign exchange.
Free Cash Flow $107.2 million. This was derived from cash flow from operations of $128.7 million minus capital expenditures of $21.5 million.
iTero Lumina scanner wand upgrades: Stronger-than-expected sales contributed to solid revenue growth in Systems and Services.
Invisalign First: Key contributor to year-over-year growth, especially for teens and kids.
Invisalign palate expander system: Contributed to year-over-year growth in North America.
DSP touch-up cases: Showed strong year-over-year growth.
APAC region: Year-over-year growth in clear aligner volume, led by China and increased adoption of Invisalign First.
EMEA region: Year-over-year growth in clear aligner volume, driven by increased utilization in adult segments and adoption of noncomprehensive Invisalign offerings.
Americas region: Year-over-year decline in clear aligner volume, offset by growth in Latin America teen segment.
Cost reduction initiatives: Realignment of business groups, workforce reduction, and optimization of manufacturing footprint to improve profitability.
Manufacturing upgrades: Transition to next-generation manufacturing technologies and increased automation.
Expansion of product offerings: Introduction of IPE and MAOB in over 70 markets, expansion of DSP offerings in Europe and Latin America, and planned introduction in APAC markets in 2026.
Integration of technologies: Piloting integration of x-ray diagnostics with iTero Lumina Scanner in select markets.
Ortho-restorative offering: Piloting to GP dentists through labs to expand Invisalign adoption.
Economic Uncertainty: The company is facing challenges due to global tariff volatility, ongoing inflation, elevated interest rates, and unstable consumer confidence, which are impacting patient traffic, orthodontic case starts, and case acceptance.
Lower-than-expected Sales: Sales of full iTero Lumina Systems and clear aligners in Europe and North America were below expectations, leading to lower revenues and operating margins.
Patient Hesitation: There is hesitation among patients toward elective procedures, influenced by financial uncertainty and less affordable financing options for orthodontic treatment and capital equipment purchases.
Shift to Metal Braces: Practices using both wires and brackets and clear aligners are shifting more case starts to metal braces, impacting the demand for clear aligners.
Seasonal and Regional Declines: Clear aligner volumes declined in North America and showed uneven patient case conversion, with a lower-than-typical seasonal uptick in case starts.
Restructuring Costs: The company plans to realign business groups, reduce the global workforce, and optimize manufacturing, incurring onetime charges of $150 million to $170 million in the second half of 2025.
Regulatory and Tariff Challenges: The company is dealing with U.S. tariffs and a VAT appeal in the U.K., which could impact pricing and operational costs.
Product Mix Shift: There is a shift to lower-priced noncomprehensive clear aligner products, which is reducing average selling prices and impacting revenue growth.
Manufacturing Costs and Efficiency: Higher manufacturing costs and tariffs are affecting gross margins, despite some savings from freight and manufacturing efficiencies.
Delayed Consumer Spending: Consumers are delaying spending on orthodontic treatments due to affordability concerns, impacting the timing and volume of case starts.
Revenue Expectations: Q3 2025 worldwide revenues are expected to be in the range of $965 million to $985 million, down sequentially from Q2 2025. Fiscal year 2025 revenue growth is expected to be flat to slightly up from 2024.
Clear Aligner Volume: Q3 2025 clear aligner volume is expected to decline sequentially due to seasonality. Fiscal year 2025 clear aligner volume growth is projected to be in the low single digits.
Clear Aligner ASPs: Q3 2025 clear aligner ASPs are expected to increase slightly sequentially due to favorable foreign exchange, partially offset by a product mix shift to lower-priced products. Fiscal year 2025 clear aligner ASPs are expected to decline year-over-year due to a continued product mix shift to lower-priced products and growth in emerging markets.
Systems and Services Revenue: Q3 2025 Systems and Services revenues are expected to decline sequentially due to seasonality. Fiscal year 2025 Systems and Services revenues are expected to grow faster than clear aligner revenues.
Gross Margin: Q3 2025 GAAP gross margin is expected to be 64% to 65%, down sequentially due to onetime charges and lower clear aligner volume. Fiscal year 2025 GAAP gross margin is expected to be 67% to 68%, down year-over-year due to onetime charges and lower clear aligner volume.
Operating Margin: Q3 2025 GAAP operating margins are expected to be 10.5% to 11.5%, down sequentially due to onetime charges and lower clear aligner volume. Fiscal year 2025 GAAP operating margin is expected to be 13% to 14%, down year-over-year due to onetime charges. Fiscal year 2025 non-GAAP operating margin is expected to be slightly above 22.5%.
Capital Expenditures: Fiscal year 2025 capital expenditures are expected to be between $100 million and $125 million, primarily for technology upgrades and maintenance.
Cost-Saving Measures: The company plans to realign business groups, reduce the global workforce, optimize manufacturing, and transition to next-generation manufacturing technologies. These actions are expected to incur onetime charges of $150 million to $170 million in the second half of 2025, with $50 million to $60 million in Q3 2025. These measures are expected to improve fiscal year 2026 operating margins by at least 100 basis points year-over-year.
Stock Repurchase Program Completion: During Q2 2025, Align Technology repurchased approximately 585,100 shares of its common stock at an average price of $164.14 per share, completing the $225 million open market repurchase initiated in Q1 2025. This completed the $1 billion stock repurchase program approved in January 2023 in its entirety.
New Stock Repurchase Authorization: In April 2025, the Board of Directors authorized a new plan to repurchase up to $1 billion of common stock, expected to be completed over a period of up to 3 years.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
